
Novartis also announced that Richard Saynor, will be appointed CEO designate of Sandoz and step down from the Executive Committee…
The pharma major also claimed that Iptacopan was well tolerated with a favorable safety profile consistent with previously reported data.
The company claims that the positive CHMP opinion is based on data from the Phase III VISION study, in which…
Reportedly, Novartis sued HEC and more than a dozen other generic drugmakers, accusing them of patent infringement, in Delaware federal…
In a press statement on Thursday, the company said that Novartis is implementing this strategy with a clear focus on…
In January this year, a three-judge panel of the CAFC issued a decision upholding the validity of the dosing regimen…
Denosumab is indicated for treating a variety of conditions, including osteoporosis in postmenopausal women, in men at increased risk of…
Moreover, the pharma company also stated that the COMCO had initiated an investigation in collaboration with the European Commission into…
The company claims that Novartis’ early-stage biologics portfolio has grown significantly in the last 15 years.
Hidradenitis suppurativa is a chronic skin condition that leads to lumps in places such as the armpits or groin. The…
The pharma major claims that Kisqali is the only CDK4/6 inhibitor with proven overall survival benefit across all its three…
The pharma major claim that Novartis’s ambition is to reduce the suffering from immunological conditions, which affect up to 4.5…
Prior to joining Merck in 2018, Dr. Marshall was a Founder and Chief Scientific Officer of Heptares Therapeutics.
According to a press statement, from September 10 to September 12, Novartis will present papers on key products which include…
The pharma major also informed that the standalone Sandoz would be headquartered in Switzerland and listed on the SIX Swiss…
No unexpected safety signals were observed and the findings from the trial will be presented at an upcoming medical meeting,…
Meanwhile, the company has also launched a potent combination of Sitagliptin and Metformin and branded it as Jankey M.
According to the generic pharmaceutical company, the submitted biosimilar was developed to have the same intravenous (iv) dosage form, route…